AVIR
AteaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
AVIR vs peer average
64/100
AVIR vs. peer average (C vs. D)
Grade spread
A 1 · C 2 · D 3 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
ABBV is the first available peer comparator.
Direct HCV commercial comparator rather than a same-market-cap peer: Atea identifies Mavyret as one of the major branded HCV regimens, making ABBV relevant for treatment-duration, cure-rate, tolerability, and market-positioning comparisons if AVIR's regimen succeeds [#10-K-2026-03-05].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
AVIR
Atea
ABBV
AbbVie
Grade
C
C
Momentum
13
92
Value
41
60
Sentiment
82
37
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Grade position vs ABBV
AVIR / ABBV
Grade Position
In line
AVIR vs. peer average (C vs. D)
64/100
Momentum
13
ABBVValue
41
ABBVSentiment
82
AVIRRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs AVIR
ABBV is the first peer returned for this comparison set.